As such, the identification of phytocompounds capable of selectively inhibiting COX-2 while avoiding the adverse cardiovascular, gastrointestinal, and renal side effects of synthetic inhibitors offers a promising path toward safer, long-term interventions for individuals with AD—especially those with comorbidities or contraindications to biologic agents. The gene discussed is PTGS2; the disease is Alzheimer disease.